Skip to content

Study · Non-randomized trial · n = 17 · 1995

5 results

Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).

Juul A, Scheike T, Nielsen CT, Krabbe S, Müller J, Skakkebaek NE

The Journal of clinical endocrinology and metabolism1 Oct 1995Cited by 33 (Europe PMC)

PMID7559897 (opens in a new tab)DOI10.1210/jcem.80.10.7559897 (opens in a new tab)PepBankPUB-07559897
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In children with central precocious puberty, serum IGF-I remained unchanged during monthly intramuscular Decapeptyl treatment.

    In plain wordsIn children with early puberty, serum IGF-I did not change during monthly Decapeptyl treatment compared with before treatment.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changeSerum IGF-I
    Study

    n = 17

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intramuscular · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Serum IGF-I levels remained unchanged during monthly im treatment with long acting GnRH analog, whereas IGFBP-3 levels significantly increased during the first year of this treatment despite unmeasurable estradiol levels.
    1 context sentence
    Summary · context
    We, therefore, studied 40 patients with idiopathic CPP that were treated for 24 months with either GnRH analog (Buserelin) in combination with cyproterone acetate (Androcur; n = 23) or with long acting GnRH analog (Decapeptyl Depot; n = 17).
  2. 02HumanNon-randomized trialEfficacy outcome

    In children with central precocious puberty, serum IGFBP-3 increased during the first year of Decapeptyl treatment.

    In plain wordsIn children with early puberty, serum IGFBP-3 increased during the first year of Decapeptyl treatment compared with before treatment.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseSerum IGFBP-3
    Study

    n = 17

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intramuscular · first yearAs given in this study (human).

    Source sentences

    Summary
    Serum IGF-I levels remained unchanged during monthly im treatment with long acting GnRH analog, whereas IGFBP-3 levels significantly increased during the first year of this treatment despite unmeasurable estradiol levels.
    1 context sentence
    Summary · context
    We, therefore, studied 40 patients with idiopathic CPP that were treated for 24 months with either GnRH analog (Buserelin) in combination with cyproterone acetate (Androcur; n = 23) or with long acting GnRH analog (Decapeptyl Depot; n = 17).
  3. 03HumanNon-randomized trialEfficacy outcome

    In children with central precocious puberty, estradiol was unmeasurable during Decapeptyl treatment.

    In plain wordsIn children with early puberty, estradiol was unmeasurable during Decapeptyl treatment.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Direction not reportedEstradiol levels
    Study

    n = 17

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · intramuscular · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Serum IGF-I levels remained unchanged during monthly im treatment with long acting GnRH analog, whereas IGFBP-3 levels significantly increased during the first year of this treatment despite unmeasurable estradiol levels.
    1 context sentence
    Summary · context
    We, therefore, studied 40 patients with idiopathic CPP that were treated for 24 months with either GnRH analog (Buserelin) in combination with cyproterone acetate (Androcur; n = 23) or with long acting GnRH analog (Decapeptyl Depot; n = 17).
  4. 04HumanNon-randomized trialEfficacy outcome

    In children with central precocious puberty, the IGF-I to IGFBP-3 molar ratio declined during Decapeptyl treatment.

    In plain wordsIn children with early puberty, the IGF-I to IGFBP-3 ratio declined during Decapeptyl treatment compared with before treatment.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseIGF-I to IGFBP-3 molar ratio
    Study

    n = 17

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intramuscular · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Thus, in both groups, the molar ratio between IGF-I and IGFBP-3 (i.e. free biologically active IGF-I) declined concomitantly with a decrease in growth velocity.
    1 context sentence
    Summary · context
    We, therefore, studied 40 patients with idiopathic CPP that were treated for 24 months with either GnRH analog (Buserelin) in combination with cyproterone acetate (Androcur; n = 23) or with long acting GnRH analog (Decapeptyl Depot; n = 17).
  5. 05HumanNon-randomized trialEfficacy outcome

    In children with central precocious puberty, growth velocity decreased during Decapeptyl treatment.

    In plain wordsIn children with early puberty, growth slowed during Decapeptyl treatment compared with before treatment.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseGrowth velocity
    Study

    n = 17

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · intramuscular · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Thus, in both groups, the molar ratio between IGF-I and IGFBP-3 (i.e. free biologically active IGF-I) declined concomitantly with a decrease in growth velocity.
    1 context sentence
    Summary · context
    We, therefore, studied 40 patients with idiopathic CPP that were treated for 24 months with either GnRH analog (Buserelin) in combination with cyproterone acetate (Androcur; n = 23) or with long acting GnRH analog (Decapeptyl Depot; n = 17).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.